BioTuesdays

Category - Developments

Transition Therapeutics sets Phase 2 SARM trial

Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has entered an agreement for an investigator-led clinical study of drug candidate, TT701, with Brigham and Women’s Hospital (BWH).Transition will support the Phase 2 study...

Novadaq Q3 revenue climbs 40%

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) reported revenue of $17-million for the third quarter this year, an increase of 40% from $12.1-million a year ago.Product sales increased by $5.2-million, or 47%, primarily...

Avivagen sets OxC-beta swine trial in Vietnam

Avivagen (TSX-V:VIV) has agreed with the National Institute of Animal Sciences for Vietnam (NIAS) to conduct a further trial of OxC-beta livestock as a feed additive for swine.Earlier this year, Avivagen and NIAS...

Obama to expand MAT in opioid addiction

President Barack Obama has tackled the opioid epidemic this week by telling health care providers across the country that access to medication-assisted treatment (MAT) must be expanded.He released an order giving...

Profound Medical presents TULSA-PRO data

Twelve-month data from Profound Medical’s (TSXV:PRN) Phase 1 clinical trial of its TULSA-PRO medical device were presented at the European Symposium on Focused Ultrasound Therapy in London.TULSA is a minimally invasive...

Subscribe

Sign up to our weekly BioTuesdays newsletter.